Literature DB >> 11751591

Ligands have various potential effects on the degradation of pregnane X receptor by proteasome.

Hisashi Masuyama1, Hideshi Inoshita, Yuji Hiramatsu, Takafumi Kudo.   

Abstract

The degradations of several nuclear receptors are involved in the proteasome-mediated pathway. In our recent experiments, we found that mouse pregnane X receptor (PXR) interacted with suppressor for gal1 (SUG1), a component of the proteasome, in a progesterone-dependent manner, but that endocrine-disrupting chemicals (EDCs), phthalic acid and nonylphenol, which activated PXR-mediated transcription, did not enhance this interaction. PXR protein levels were markedly increased in the presence of proteasome inhibitors, suggesting that PXR may be degraded by proteasome. Furthermore, in the absence of ongoing protein synthesis, there is much slower degradation of PXR in the presence of phthalic acid compared with that in the presence of progesterone. The transient expression studies demonstrated that overexpression of wild-type SUG1 generated proteolytic PXR fragments, and these productions were blocked by a proteasome inhibitor. Functionally, expression of SUG1 inhibited PXR- and progesterone-mediated transcription. Moreover, in the presence of EDCs, SUG1 had no effect on the transcription. These findings indicate that the interaction between PXR and SUG1 may be involved in the proteasome-mediated degradation. Moreover, an EDC strongly blocks the degradation of PXR compared with progesterone, suggesting that EDCs may affect PXR-mediated transcription of target genes through up-regulation of the PXR protein level.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11751591     DOI: 10.1210/endo.143.1.8578

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  17 in total

Review 1.  A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha, and LXRbeta.

Authors:  Sean Ekins; Leonid Mirny; Erin G Schuetz
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

2.  SUMOylation and Ubiquitylation Circuitry Controls Pregnane X Receptor Biology in Hepatocytes.

Authors:  Wenqi Cui; Mengxi Sun; Nadezhda Galeva; Todd D Williams; Yoshiaki Azuma; Jeff L Staudinger
Journal:  Drug Metab Dispos       Date:  2015-06-10       Impact factor: 3.922

3.  RBCK1, an E3 ubiquitin ligase, interacts with and ubiquinates the human pregnane X receptor.

Authors:  Ritu Rana; Sherry Coulter; Harriet Kinyamu; Joyce A Goldstein
Journal:  Drug Metab Dispos       Date:  2012-11-15       Impact factor: 3.922

4.  Endocrine disruptors provoke differential modulatory responses on androgen receptor and pregnane and xenobiotic receptor: potential implications in metabolic disorders.

Authors:  Nagendra Kumar Chaturvedi; Sanjay Kumar; Seema Negi; Rakesh K Tyagi
Journal:  Mol Cell Biochem       Date:  2010-09-10       Impact factor: 3.396

Review 5.  Role of CAR and PXR in xenobiotic sensing and metabolism.

Authors:  Yue-Ming Wang; Su Sien Ong; Sergio C Chai; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-05-03       Impact factor: 4.481

Review 6.  Post-translational modification of pregnane x receptor.

Authors:  Jeff L Staudinger; Chenshu Xu; Arunima Biswas; Sridhar Mani
Journal:  Pharmacol Res       Date:  2011-03-21       Impact factor: 7.658

Review 7.  Post-translational and post-transcriptional modifications of pregnane X receptor (PXR) in regulation of the cytochrome P450 superfamily.

Authors:  Tomas Smutny; Sridhar Mani; Petr Pavek
Journal:  Curr Drug Metab       Date:  2013-12       Impact factor: 3.731

Review 8.  PXR: More Than Just a Master Xenobiotic Receptor.

Authors:  Peter O Oladimeji; Taosheng Chen
Journal:  Mol Pharmacol       Date:  2017-11-07       Impact factor: 4.436

Review 9.  CAR and PXR: the xenobiotic-sensing receptors.

Authors:  Yoav E Timsit; Masahiko Negishi
Journal:  Steroids       Date:  2006-12-20       Impact factor: 2.668

10.  Interactions of methoxyacetic acid with androgen receptor.

Authors:  Gargi Bagchi; Christopher H Hurst; David J Waxman
Journal:  Toxicol Appl Pharmacol       Date:  2008-04-07       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.